2023
Efficacy of Osimertinib in Patients with Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations
Grant M, Aredo J, Starrett J, Stockhammer P, van Rosenburgh I, Wurtz A, Piper-Valillo A, Piotrowska Z, Falcon C, Yu H, Aggarwal C, Scholes D, Patil T, Nguyen C, Phadke M, Li F, Neal J, Lemmon M, Walther Z, Politi K, Goldberg S. Efficacy of Osimertinib in Patients with Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations. Clinical Cancer Research 2023, 29: of1-of8. PMID: 36913537, PMCID: PMC10493186, DOI: 10.1158/1078-0432.ccr-22-3497.Peer-Reviewed Original ResearchMeSH KeywordsAniline CompoundsCarcinoma, Non-Small-Cell LungErbB ReceptorsExonsHumansLung NeoplasmsMutationProtein Kinase InhibitorsRetrospective StudiesSequence DeletionConceptsProgression-free survivalNon-small cell lung cancerInferior progression-free survivalMulticenter retrospective cohortEfficacy of osimertinibMulti-institutional cohortCell lung cancerExon 19 deletion mutationUncommon EGFRRetrospective cohortClinical outcomesClinical efficacyLung cancerOsimertinib efficacyEGFR mutationsPreclinical modelsEx19delPatientsAACR Genie databaseLater linesOsimertinibMutant cohortFirst lineCohortEfficacy
2020
HDAC inhibition synergizes with ALK inhibitors to overcome resistance in a novel ALK mutated lung adenocarcinoma model
Stockhammer P, Ho CSL, Hegedus L, Lotz G, Molnár E, Bankfalvi A, Herold T, Kalbourtzis S, Ploenes T, Eberhardt WEE, Schuler M, Aigner C, Schramm A, Hegedus B. HDAC inhibition synergizes with ALK inhibitors to overcome resistance in a novel ALK mutated lung adenocarcinoma model. Lung Cancer 2020, 144: 20-29. PMID: 32353632, DOI: 10.1016/j.lungcan.2020.04.002.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinoma of LungCarcinoma, Non-Small-Cell LungDrug Resistance, NeoplasmHumansLung NeoplasmsMutationProtein Kinase InhibitorsConceptsALK tyrosine kinase inhibitorsCell linesALK fusion oncogeneDistinct resistance mutationsTreatment-naïve ALKMalignant pleural effusionPost-treatment tumorsLung cancer modelPan-HDAC inhibitorsNovel therapeutic approachesTyrosine kinase inhibitorsMesenchymal transition (EMT) markersLung adenocarcinoma modelTime of resistancePleural effusionALK inhibitionLung adenocarcinomaSubcutaneous xenograftsALK inhibitorsTherapeutic approachesCell line pairsCancer modelAdenocarcinoma modelHDAC inhibitionTransition markers